Investigational drug · Phase 2
ARGX-119
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Spinal Muscular Atrophy (SMA).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "ARGX-119"
First trial start
2025
Dec 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ARGX-119", any sponsor or status.
Conditions studied
As listed on its trial records.
- Spinal Muscular Atrophy (SMA)
Approved drugs for the same conditions: Spinal muscular atrophy · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ARGX-119" as an intervention, largest first.
- A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy ParticipantsPivotal-lookingCompleted
argenxargenx (ARGX)
NCT05670704 · 112 participants · Start Feb 21, 2023 · Primary completion Aug 8, 2024
Drug: ARGX-119 · For: Healthy Volunteers
Sites: Groningen, Netherlands
argenxargenx (ARGX)
NCT07287982 · 60 participants (planned) · Start Dec 19, 2025 · Primary completion May 28, 2029
Drug: ARGX-119 IV · For: Spinal Muscular Atrophy (SMA)
Sites: Little Rock, Arkansas; San Diego, California; Stanford, California · 46 sites in all
- A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)Terminated
argenxargenx (ARGX)
NCT06441682 · 60 participants · Start Oct 23, 2024 · Primary completion Aug 12, 2026
Drug: ARGX-119 · For: Amyotrophic Lateral Sclerosis
Sites: Leuven, Belgium; Edmonton, Canada; Montreal, Canada · 9 sites in all
- A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)Active, not recruiting
argenxargenx (ARGX)
NCT06436742 · 15 participants · Start Sep 24, 2024 · Primary completion Aug 24, 2027
Drug: ARGX-119 · For: Congenital Myasthenic Syndrome; CMS
Sites: Sacramento, California; Chicago, Illinois; Ottawa, Canada · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Gene-specific response to muscle specific kinase agonist antibody in the treatment of congenital myasthenic syndromes.
Ho K, Adjei-Afriyie O, Carmona-Martinez R, et al. · Brain Commun 2026
- First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Muscle-Specific Kinase Agonist Adimanebart (ARGX-119).
Bragt TV, Kneip C, Priem S, et al. · J Clin Pharmacol 2026
- Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models.
Lim JL, Jensen SM, Plomp JJ, et al. · iScience 2025
- ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome.
Vanhauwaert R, Oury J, Vankerckhoven B, et al. · Sci Transl Med 2024
Also in development for Spinal Muscular Atrophy (SMA)
- RO7204239Phase 33 trials
Roche (Genentech) · Obesity, Overweight, Overweight With One Weight Related Comorbidity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from argenx.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.